REFERENCES
1. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015;386:1546-55.
2. Hou J, Liu Z, Gu F. Epidemiology and prevention of hepatitis B virus infection. Int J Med Sci 2005;2:50-7.
3. Tai DI, Jeng WJ, Lin CY. A global perspective on HBV-related SNPs and evolution during human migration. Hepatol Commun 2017;1:1005-13.
4. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009;373:582-92.
5. Liaw YF, Tai DI, Chu CM, Lin DY, Sheen IS, et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis: a prospective study. Gastroenterology 1986;90:263-7.
6. Liaw YF, Tai DI, Chen TJ, Chu CM, Huang MJ. Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma. Liver 1986;6:133-7.
7. Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017;11:317-70.
8. Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol 2014;20:4115-27.
9. Tsay PK, Tai DI, Chen YM, Yu CP, Wan SY, et al. Impact of gender, viral transmission and aging in the prevalence of hepatitis B surface antigen. Chang Gung Med J 2009;32:155-64.
10. Cheng HT, Chang YH, Chen YY, Lee TH, Tai DI, et al. AFP-L3 in chronic liver diseases with persistent elevation of alpha-fetoprotein. J Chin Med Assoc 2007;70:310-17.
11. Choi J, Kim GA, Han S, Lee W, Chun S, et al. Longitudinal assessment of three serum biomarkers to detect very early stage hepatocellular carcinoma. Hepatology 2019;69:1983-94.
12. Xie H, Xue YQ, Liu P, Zhang PJ, Tian ST, et al. Multi-parameter gene expression profiling of peripheral blood for early detection of hepatocellular carcinoma. World J Gastroenterol 2018;24:371-8.
13. Ng CKY, Di Costanzo GG, Terracciano LM, Piscuoglio S. Circulating cell-free DNA in hepatocellular carcinoma: current insights and outlook. Front Med (Lausanne) 2018;5:78.
14. Pezzuto F, Buonaguro L, Buonaguro FM, Tornesello ML. The role of circulating free DNA and MicroRNA in non-invasive diagnosis of HBV- and HCV-related hepatocellular carcinoma. Int J Mol Sci 2018;19:E1007.
15. Zacharakis G, Aleid A, Aldossari KK. New and old biomarkers of hepatocellular carcinoma. Hepatoma Res 2018;4:65.
16. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the liver. J Hepatol 2001;35:421-30.
17. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335-52.
18. 17Lin CL, Kao JH. Risk stratification for hepatitis B virus related hepatocellular carcinoma. J Gastroenterol Hepatol 2013;28:10-7.
19. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.
20. Ronot M, Pommier R, Dioguardi Burgio M, Purcell Y, et al. Hepatocellular carcinoma surveillance with ultrasound-cost-effectiveness, high-risk populations, uptake. Br J Radiol 2018;91:20170436.
21. Wang C, Chen V, Vu V, Le A, Nguyen L, et al. Poor adherence and low persistency rates for hepatocellular carcinoma surveillance in patients with chronic hepatitis B. Medicine (Baltimore) 2016;95:e4744.
22. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:417-22.
23. Chen K, Chang PE, Goh GBB, Tan CK. Surveillance for hepatocellular carcinoma - current status and advances. Hepatoma Res 2018;4:72.
24. Tai DI, Lin SM, Sheen IS, Chu CM, Lin DY, et al. Long-term outcome of HBeAg-negative HBsAg carriers in relation to changes of alanine aminotransferase levels over time. Hepatology 2009;49:1859-67.
25. Tai DI, Tsay PK, Chen WT, Chu CM, Liaw YF. Relative roles of HBsAg seroclearance and mortality in the decline of HBsAg prevalence with increasing age. Am J Gastroenterol 2010;105:1102-9.
26. Rode A, Bancel B, Douek P, Chevallier M, Vilgrain V, et al. Small nodule detection in cirrhotic livers: evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver. J Comput Assist Tomogr 2001;25:327-36.
27. Jo PC, Jang HJ, Burns PN, Burak KW, Kim TK, et al. Integration of contrast-enhanced US into a multimodality approach to imaging of nodules in a cirrhotic liver: how I do it. Radiology 2017;282:317-31.
28. Inchingolo R, De Gaetano AM, Curione D, Ciresa M, Miele L, et al. Role of diffusion-weighted imaging, apparent diffusion coefficient and correlation with hepatobiliary phase findings in the differentiation of hepatocellular carcinoma from dysplastic nodules in cirrhotic liver. Eur Radiol 2015;25:1087-96.
29. Yin CQ, Yuan CH, Qu Z, Guan Q, Chen H, et al. Liquid biopsy of hepatocellular carcinoma: circulating tumor-derived biomarkers. Dis Markers 2016;2016:1427849.
